A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification

Completed · Phase 3

Conditions studied: Diabetes, Diabetes Mellitus, Type 2

In brief

This trial is conducted globally. The aim of the trial is to compare sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously treated with insulin degludec/liraglutide and metformin and in need of further intensification. This is an extension to trial NN9068-3952, NCT01952145 (DUAL™ V).

Key facts

Study ID

NCT02100475

Run by

Novo Nordisk A/S

People needed

31

Starts

2014-04-01

Expected to finish

2015-04-01

Last updated by the study team

2017-01-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Completion (Visit 28) of NN9068-3952 with insulin degludec/liraglutide + metformin
• HbA1c (glycosylated haemoglobin) above or equal to 7 percent at Visit 27 of NN9068-3952 trial

You may not qualify if…

• Clinically significant diseases of the major organ systems
• Screening calcitonin above or equal to 50 ng/L

Where it is running

• Novo Nordisk Investigational Site — Fort Lauderdale, Florida, United States
• Novo Nordisk Investigational Site — Gurnee, Illinois, United States
• Novo Nordisk Investigational Site — Lexington, Kentucky, United States
• Novo Nordisk Investigational Site — Slidell, Louisiana, United States
• Novo Nordisk Investigational Site — Altoona, Pennsylvania, United States
• Novo Nordisk Investigational Site — Renton, Washington, United States
• Novo Nordisk Investigational Site — Buenos Aires, Argentina
• Novo Nordisk Investigational Site — Capital Federal, Argentina
• Novo Nordisk Investigational Site — Corrientes, Argentina
• Novo Nordisk Investigational Site — Salta, Argentina
• Novo Nordisk Investigational Site — Zárate, Argentina
• Novo Nordisk Investigational Site — Wollongong, New South Wales, Australia
• Novo Nordisk Investigational Site — Herston, Queensland, Australia
• Novo Nordisk Investigational Site — Ipswich, Queensland, Australia
• Novo Nordisk Investigational Site — Robina, Queensland, Australia
• Novo Nordisk Investigational Site — East Ringwood, Victoria, Australia
• Novo Nordisk Investigational Site — Athens, Greece
• Novo Nordisk Investigational Site — Ioannina, Greece
• Novo Nordisk Investigational Site — Larissa, Greece
• Novo Nordisk Investigational Site — Thessaloniki, Greece
• Novo Nordisk Investigational Site — Thessaloniki, Greece
• Novo Nordisk Investigational Site — Eger, Hungary
• Novo Nordisk Investigational Site — Győr, Hungary
• Novo Nordisk Investigational Site — Gyula, Hungary
• Novo Nordisk Investigational Site — Fresno, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.